Premium
Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicity
Author(s) -
Hayes F. Ann,
Green Alexander A.,
Casper James,
Cornet Joann,
Evans William E.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19811015)48:8<1715::aid-cncr2820480805>3.0.co;2-y
Subject(s) - medicine , hypomagnesemia , toxicity , cyclophosphamide , neuroblastoma , cisplatin , chemotherapy , oncology , urology , magnesium , materials science , genetics , metallurgy , cell culture , biology
Cis‐dichlorodiammineplatinum (CDDP) and VM26, both of which have been proven efficient in treating neuroblastoma, were combined in a sequential schedule and administered to 22 children with disseminated neuroblastomas resistant to treatment with cyclophosphamide and doxorubicin (Adriamycin). During this same study, 14 children were prospectively evaluated for the effect of CDDP on magnesium metabolism and the effect of the induced hypomagnesemia on parathyroid function. Complete or partial tumor responses were achieved in six and nine cases, respectively and were of prolonged duration (longer than six months) in eight of the 15 responding. It was also shown that CDDP‐induced hypomagnesemia is the result of excessive renal loss and is severe enough to interfere with the normal parathormone response to hypocalcemia.